retatrutide ly3437943 triple agonist glp-1 gip glucagon mechanism the wonder drug: What's Established, What's Plausible, What's Still a Hypothesis — WellFounded - Founders Health & Concierge Performance Medicine Retatrutide: The Triple Agonist That

T2D: type 2 diabetes

The phase 2 trial published in The New England Journal of Medicine in 2023 enrolled adults with obesity without type 2 diabetes and demonstrated dose-dependent weight loss of up to 24.2% of body weight at the highest dose over 48 weeks results that attracted considerable scientific and media attention

Clinical trials have demonstrated substantial weight loss outcomes, with patients losing an average of approximately 15% of their body weight over 68 weeks with semaglutide 2.4 mg weekly in the STEP 1 trial

Within each category, supplements with therapeutic potential are listed

GLP-1 Receptor Agonist Market Opportunities: Expanded cardiovascular indications and biosimilar development creating transformative GLP-1 receptor agonist market opportunities The cardiovascular indication expansion following SELECT trial approval for semaglutide in cardiovascular risk reduction in obese non-diabetic patients is qualitatively important because it changes who prescribes GLP-1 drugs